Hone Health Review: Is TRT a Longevity Plan?

The one-sentence version

Hone Health publishes more of its prices than most providers in our ranking, and is one of the least evidence-honest. Every medication it sells carries a published monthly figure, both membership tiers are posted, and the site states plainly: "No commitments. Cancel anytime." There is no hidden quarterly prepay, no introductory rate that expires, no consult-to-learn-pricing wall. It grades B, 8 points out of 14. That price clarity is genuinely rare, and it is worth crediting loudly. What Hone then does with that clarity is file testosterone and hormone replacement under "longevity" — a framing that the FDA-approved testosterone label explicitly declines to support, and that the largest randomized trials of testosterone in middle-aged and older men do not bear out. Buy it for what it is: a well-run, honestly-priced hormone clinic. Do not buy the healthspan story bolted onto the front of it. For the map of what is actually proven in this field, start with longevity medicine: what's proven vs hyped.

What Hone Health is, and who it's for

Hone is a telehealth hormone-optimization platform, sold in two tracks — a men's track built around testosterone replacement therapy (TRT; see our Taurus Meds review and Male Excel review for two TRT-first competitors), and a women's track built around menopause and hormone replacement (see our Winona review for a menopause-focused alternative) — with a "longevity" shelf sitting alongside both.² Corporately, care is delivered through independent practices: the site states that "Hone-affiliated medical practices are independently owned and operated by licensed physicians who provide services using the Hone telehealth platform," with physician recruitment run through a partnership with Broad Health.

The flow is lab-first and gated, in that order:

1. 1.Buy the biomarker test — $65. Hone describes it as "in-depth, 50-biomarker blood testing" plus health history and validated questionnaires. You either go to a partner lab or, where available, Hone sends a phlebotomist to you at no extra charge.
2. 2.Take a telehealth consult with a licensed physician, included in that $65.
3. 3.Pick a membership, then buy medication on top of it.

Nothing is prescribed before the labs exist. That gate is a genuine strength and the opposite of a rubber-stamp questionnaire — clinical oversight is one of the five factors in our grading methodology.

What it actually costs — and the tier that isn't the tier

Entry: $65 for the 50-biomarker panel plus the physician consult and a plan. Hone calls this "100% risk-free."

Basic membership: $25/month, "plus cost of medication." What that buys, in Hone's own words: key biomarkers re-tested every 6 months, "the ability to purchase telehealth consults with expert licensed physicians," and "members-only pricing on BASIC medications & supplements."

Read that middle clause again. On the $25 tier, physician consults are not included — they are a separate purchase, and Hone does not publish what one costs. That is the single gap in an otherwise exemplary pricing page, and it matters, because a hormone protocol without follow-up consultation is not a protocol.

Premium membership: $155/month, "plus cost of medication." This includes the consults, the personalized protocol (testosterone, estrogen, weight loss), and "retesting + follow-ups every 90 days." Hone's own page labels this tier "Chosen by 95% of patients."

That last line is the honest headline. If 95% of buyers land on Premium, the real price of Hone is $155/month, not $25 — and a review that quotes the $25 figure as the price of entry is quoting a tier Hone itself says 95% of members do not use. To Hone's credit, it publishes the 95% figure itself rather than hiding behind the cheap tier.

Medication is billed separately, and every drug is priced. On the men's TRT page: testosterone injections from $28/mo, testosterone cream from $60/mo, troches from $60/mo, clomiphene citrate from $38/mo, enclomiphene from $42/mo, anastrozole $22/mo — each stated as "+ membership." On the women's menopause page: estradiol patch $58/mo, bi-est cream $80/mo, progesterone $49/mo, progesterone cream $79/mo, Estrace estradiol cream $40/mo, Vagifem $65/mo, DHEA cream $56/mo, estriol vaginal cream $58/mo. On the longevity shelf: NAD+ $165/mo, glutathione $90/mo, vitamin B12 $60/mo, low-dose naltrexone $38/mo, metformin $25/mo, omega-3-acid ethyl esters $20/mo.

So the real all-in number, for the typical buyer: $65 to start, plus $155/month Premium, plus $28/month for testosterone injections — about $2,260 in the first year, and about $2,196 a year thereafter. That is a real, buildable figure you can compute before entering a card number, which is more than most of this category permits. Compare it against the price bands in how much a longevity clinic costs.

And the commitment check comes back clean. Hone states "No commitments. Cancel anytime." We found no product page where the advertised rate depended on a 3-, 6- or 12-month prepay. That is not the norm — the AgelessRx review documents a competitor whose headline prices are quarterly-plan and, in one case, introductory rates — and Hone deserves the contrast drawn in its favor.

What's included, what's extra

Included at Premium: quarterly retesting, physician consults and follow-ups, the personalized protocol, and members-only medication pricing.

Extra, always: the medication itself, on every tier. The membership fee buys the medical relationship, not the drug.

Extra on Basic: the consults. Price not published — the one figure Hone withholds.

Not offered: imaging, epigenetic-age testing, or the broad screening panel a diagnostics-led program provides. Hone's 50 markers are hormone-weighted by design, and are not a substitute for the outcome-validated core we describe in what longevity biomarker panels actually test.

Clinical oversight: who prescribes, and what they check

Structurally, this is good. Labs come before prescriptions. Premium members are retested every 90 days, which is the correct cadence for anyone on exogenous hormones — testosterone therapy requires periodic haematocrit, PSA and blood-pressure monitoring, and a quarterly rhythm supports that.

Two deductions. First, Hone names no medical director. Its how-it-works page does name four physicians, with credentials: Janel Meric, M.D., Alexander Watson, M.D., Raheleh Sarbaziha, M.D. and Timothy Vachris, M.D., and its terms name the affiliated medical groups (Broad Health P.A., Adrian Rawlinson, M.D., P.C. d/b/a Broad Health of California, Broad Health of NC, P.C., Ivee Medical PC and IV Medical New York, P.L.L.C.). What is still missing is a named medical director and any NPI numbers you could check, which a competitor like AgelessRx does publish. Second, the Basic tier decouples oversight from the membership. A patient on $25/month with a testosterone prescription and no purchased consult is a patient on hormones without scheduled clinician contact — a configuration the platform permits.

The evidence behind what it sells

This is where Hone's marketing outruns its data.

Testosterone, on the FDA label. Testosterone cypionate is approved "for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone" — specifically primary hypogonadism and hypogonadotropic hypogonadism. The label then carries an explicit Limitation of Use: "Safety and efficacy of testosterone cypionate in men with 'age-related hypogonadism' (also referred to as 'late-onset hypogonadism') have not been established." It also warns that "Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time," and notes that "Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy"¹. Age-related low testosterone — the exact demographic a direct-to-consumer TRT platform serves — is the one indication the label declines to endorse.

What the big trials found. The large testosterone trials are reassuring on heart attacks and strokes in men who genuinely need treatment, but they also recorded more atrial fibrillation, blood clots in the lung and acute kidney injury on testosterone, more fractures rather than fewer, and a benefit that was mostly sexual function, not energy or vitality. None of them measured lifespan. A therapy marketed for strength and vitality has no trial showing it delivers either as an anti-aging treatment. Our full read is in testosterone, TRT and longevity.

The diagnostic bar. Low testosterone is normally diagnosed only when symptoms come with a clearly low morning testosterone level that is confirmed on a repeat test. A single at-home draw is a screen, not a diagnosis. If Hone's protocol repeats the morning measurement before prescribing, that is worth knowing; the public pages do not say.

The women's track. Menopausal hormone therapy for vasomotor symptoms is legitimate, well-established medicine — that is not in dispute. What is in dispute is calling it longevity care. The best-known large trial of combined hormone therapy was stopped early because risks outweighed benefits; it tested older products in women averaging 63, so it does not directly indict the transdermal estradiol and micronized progesterone Hone sells near the menopausal transition. But it is precisely why "hormones extend healthspan" is not a claim anyone gets to assert casually. See HRT, menopause and longevity.

The longevity shelf, claim by claim. Hone's own longevity page states that NAD+ "may increase lifespan, boost strength and physical performance, help with weight loss," and that metformin "promotes healthy aging and longevity." Neither survives contact with the human data. NAD+ precursors reliably raise NAD+ levels, but no human trial shows that translates into longer life or better aging — and Hone charges $165/month for it, the most expensive item on its longevity shelf and the one with the weakest support; our full read is in NAD+ for longevity. Metformin's longevity case in people without diabetes is observational, and in older adults it can blunt the fitness gains from exercise. See metformin for longevity.

Where it's weak

1. "Longevity" is doing work the evidence doesn't support. Hone's own copy asserts that NAD+ may increase lifespan and metformin promotes longevity, and files testosterone under healthspan. Overselling mechanism as outcome is the field's most common failure, and this is a textbook case.

2. No named medical director. Four physicians are named, but for a platform whose entire value is the medical relationship, not naming who is clinically in charge, or any NPI number you could check, is a real gap.

3. The $25 tier is close to a decoy. It excludes the consults, does not publish their price, and by Hone's own admission is chosen by 5% of patients. Quoting "$25/month" as Hone's price is quoting the tier Hone itself reports 95% of members do not buy.

4. Vertical dispensing. Hone tests you, interprets the result, prescribes, and sells the drug. That is common in telehealth and not disqualifying, but it raises the bar on the claims — and the claims are where Hone falls short.

5. The panel is hormone-weighted. Fifty markers sounds broad, but the tilt is toward the sex-hormone axis. If your goal is the cheap, outcome-validated core, a broad DTC panel does it better; see best longevity blood test services.

6. The biggest levers aren't on the panel at all. Cardiorespiratory fitness and grip strength are among the strongest predictors of how long people live. Neither is a hormone, and neither is billed monthly. See VO₂ max and longevity and grip strength and longevity.

Who should skip it

• •Anyone buying TRT as an anti-aging intervention. The FDA label declines to endorse it for age-related low testosterone, and the large trials recorded more atrial fibrillation, lung clots, kidney injury and more fractures on testosterone than placebo.
• •Anyone whose testosterone is normal. A number in range plus fatigue is not hypogonadism, and the standard diagnostic bar is symptoms plus clearly low, repeated morning measurements.
• •Anyone comparing on the $25 tier. Without a purchased consult it is a monitoring subscription, not care.
• •Anyone buying NAD+ at $165/month. That is the priciest item on Hone's shelf, sold on a claim ("may increase lifespan") that no human trial supports.
• •Anyone who wants broad diagnostics. A hormone-weighted 50-marker panel is not a comprehensive workup — a lab membership does that job better, as we cover in longevity clinics vs lab memberships.

How it compares to the rest of our ranking

Against AgelessRx, the two fail in mirror-image ways. AgelessRx charges no membership and imposes no lab gate — structurally the better deal — but advertises "Starting at $X" floors whose billing terms are largely undisclosed, and on rapamycin publishes no month-to-month price at all. Hone gates everything behind a $65 test and a monthly fee, then prices every single drug in plain sight with no commitment. Pick Hone if knowing the bill in advance matters most; pick AgelessRx if avoiding a membership matters most — and note that AgelessRx's menu is longevity-first while Hone's is hormone-first.

Against Lifeforce — $349 starter plus $129/month — Hone is cheaper to enter ($65 vs $349) and slightly dearer to run at Premium, with a similar hormone tilt and a similar own-products conflict. The two are close substitutes; Hone's per-drug price list is the cleaner of the two.

Against a pure lab membership like Function Health, the difference is treat-versus-test: Function surfaces 100+ markers and hands you off, Hone runs a narrower panel and prescribes off it. Hone is the more useful product if you actually need a prescription, and the worse one if you want breadth.

The full graded field sits at our longevity provider rankings.

The grade, against our rubric

• •Price transparency — 0 of 4. Every tier and every drug is priced, with no commitment, but there is no single all-in figure: a month on Hone is the $65 assessment, then a membership, then the medication billed on top.
• •Longevity line — 4 of 4. NAD+ and hormone optimization are both on the menu, alongside a "Live Longer & Better" track.
• •Clinical oversight — 2 of 2. A licensed physician's consult is included in the $65 assessment, and labs come before any prescription.
• •Pharmacy quality — 0 of 2. Hone describes a network of pharmacies and does not name the one that fills your prescription or state a 503A standard on its main site.
• •Human support — 2 of 2. Clinical support sits inside the membership rather than being billed per contact.

That lands a B, 8 points out of 14. Hone is a competently run, unusually honest-about-money hormone platform wearing a longevity costume. Strip the costume off and the underlying service is fine; leave it on and you are paying a healthspan premium for a symptom treatment.

Bottom line

Hone Health does the thing this site was built to reward: it publishes what everything costs. Both membership tiers, every medication, the entry price, and an explicit "No commitments. Cancel anytime" — there is no quarterly prepay and no expiring introductory rate. Only the Basic tier's consult price is withheld, and Hone even discloses that 95% of its patients choose the $155 tier rather than letting the $25 headline do the work.

What it does badly is the claim. Testosterone's own FDA label states that safety and efficacy in age-related hypogonadism have not been established; the large trials recorded more atrial fibrillation, lung clots and kidney injury on treatment, and more fractures, not fewer; the benefit they found was in sexual function, not vitality. Add "NAD+ may increase lifespan" at $165/month and "metformin promotes longevity" at $25/month and you have a pricing page we would hold up as a model attached to an evidence page we would not.

Buy Hone if you have symptoms and genuinely low, repeatedly-confirmed hormone levels, and you want that treated by a telehealth service that will tell you the bill in advance. Skip it if you are buying the healthspan story — and put the money into the two levers that outpredict almost every blood marker and are not for sale on any membership tier. Our full graded field is at our longevity provider rankings.